MARKET

ORGS

ORGS

Orgenesis Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.81
+0.17
+3.01%
After Hours: 5.75 -0.06 -1.03% 16:40 07/14 EDT
OPEN
5.66
PREV CLOSE
5.64
HIGH
5.81
LOW
5.53
VOLUME
35.02K
TURNOVER
--
52 WEEK HIGH
8.20
52 WEEK LOW
2.350
MARKET CAP
127.80M
P/E (TTM)
-4.2144
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ORGS stock price target is 9.00 with a high estimate of 9.00 and a low estimate of 9.00.

EPS

ORGS News

More
Orgenesis partners with Educell to conduct cell-based research programs
Seeking Alpha - Article · 20h ago
Orgenesis To Collaborate With Educell To Conduct Clinical Validation Of Cell Therapies Using Orgenesis' Proprietary POCare Technologies For The Generation And Expansion Of T-Cells
GERMANTOWN, Md., July 14, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) (“Orgenesis” or the “Company”), a pioneering global biotech company committed to accelerating commercialization and
Benzinga · 20h ago
Orgenesis Added to Russell 3000® Index
GlobeNewswire · 06/29 13:00
Russell adds lineup of healthcare firms to key indexes
Seeking Alpha - Article · 06/29 12:25
Orgenesis Added To Russell 3000 Index
GERMANTOWN, Md., June 29, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercialization and
Benzinga · 06/29 12:19
Orgenesis collaborates with Leidos on potential treatment of COVID-19
Seeking Alpha - Article · 06/22 12:51
Orgenesis and Leidos Collaborate on Potential Treatment for COVID-19
Orgenesis recently acquired the assets of Tamir Biotechnology, Inc., including Ranpirnase, a broad spectrum anti-viral agent. Ranpirnase catalyzes the degradation of RNA, and mediates several essential biological activities, including the regulation of cell p
GlobeNewswire · 06/22 12:00
Orgenesis Reports Collaboration With Edith Wolfson Medical Center To Conduct Study Using Co. Proprietary POCare Technologies For Generation, Expansion Of Tumor Infiltrating Lymphocytes
Orgenesis Inc. (NASDAQ:ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercialization and transforming the delivery of cell and gene
Benzinga · 06/01 13:39

Industry

Biotechnology & Medical Research
+2.63%
Pharmaceuticals & Medical Research
+1.70%

Hot Stocks

Symbol
Price
%Change

About ORGS

Orgenesis Inc. is a biopharmaceutical company. The Company is developing, manufacturing and processing of technologies and services in the cell and gene therapy industry. The Company operates a point-of-care (POCare) cell therapy platform (POC). The POC platform develops Advanced Therapy Medicinal Products (ATMPs) through collaborations and in-licensing with other pre-clinical and clinical-stage biopharmaceutical companies and research and healthcare institutes to bring such ATMPs to patient. The POC platform include a multitude of cell therapies, including autoimmune, oncologic, neurologic and metabolic diseases and other indications.
More

Webull offers kinds of Orgenesis Inc stock information, including NASDAQ:ORGS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORGS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ORGS stock methods without spending real money on the virtual paper trading platform.